Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.47 |
| ▸ | MAOB | P27338 | 6/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | XBP1 | P17861 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7892772 | 0.77 | NPC1 (0.45) | MAOAMAOBEGFRALDH1A1MEN1 | |
| SCHEMBL11609339 | 0.74 | MAOA (0.40) | MAOAMAOBEGFRALDH1A1MAPT | |
| SCHEMBL14958 | 0.73 | MAOA (0.52) | MAOAMAOBEGFRALDH1A1MAPT | |
| SCHEMBL6320924 | 0.73 | ALDH1A1 (0.61) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL879474 | 0.73 | ALDH1A1 (0.61) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL7892788 | 0.72 | PTGS2 (0.41) | MAOAMAOBALDH1A1MAPTLMNA | |
| SCHEMBL20628290 | 0.72 | ALDH1A1 (0.49) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL9496848 | 0.72 | SMN1; SMN2 (0.45) | MAOAMAOBALDH1A1MAPTLMNA | |
| SCHEMBL7900084 | 0.72 | MAOA (0.42) | MAOAMAOBALDH1A1MAPT | |
| SCHEMBL7900060 | 0.72 | ALDH1A1 (0.66) | MAOAMAOBALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3273011-A | — | — | None | — | — | JP | disclosed |
| US-10342744-B2 | Compositions with controlled network structure | IVOCLAR VIVADENT AG (LI) | 2019-07-09 | — | — | US | disclosed |
| US-20170172855-A1 | Compositions With Controlled Network Structure | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2017-06-22 | — | — | US | disclosed |
| US-20170156993-A1 | DENTAL MATERIALS WITH DEBONDING-ON-DEMAND PROPERTIES | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2017-06-08 | — | — | US | disclosed |
| WO-2013063214-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| JP-H03273011-A | ORGANIC GLASS | TOKUYAMA SODA CO LTD | 1991-12-04 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170172855-A1 | Compositions With Controlled Network Structure | NCLN, RAD51, SMCHD1 | MAOA 930/4885MAOB 1883/4885EGFR 4652/4885 |
| US-10342744-B2 | Compositions with controlled network structure | NCLN, RAD51, SMCHD1 | MAOA 930/4885MAOB 1883/4885EGFR 4652/4885 |
| US-20170156993-A1 | DENTAL MATERIALS WITH DEBONDING-ON-DEMAND PROPERTIES | DCLRE1A, RAD51, TERB1 | MAOA 3809/4885MAOB 3662/4885EGFR 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.